Full-Time
Posted on 10/6/2025
Specialty pharmaceutical developer, manufacturer, distributor
No salary listed
St. Louis, MO, USA + 1 more
More locations: Kansas City, MO, USA
In Person
Local travel; some overnight required, may vary depending on the region.
| , |
Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Hazelwood, Missouri
Founded
1867
Help us improve and share your feedback! Did you find this helpful?
Performance Bonus
Relocation Assistance
Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...
Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.
Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.
Mallinckrodt has reached a milestone in a $7 billion merger deal.
Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.